|CANCER & TREATMENTS FOR CANCER CENTER PATIENTS PREVENTION & RISK ASSESSMENT CLINICAL TRIALS & RESEARCH LIVING WITH CANCER|
Please note: This article is part of the Cancer Center's News Archive and is here for historical purposes. The information and links may no longer be up-to-date.
Michigan Oncology Journal Summer 2001
Due to the recent controversy in the literature of the value of radiation following mastectomy in patients with 1 to 3 positive nodes, SWOG has opened a new phase III trial in stage II breast cancer with 1 to 3 positive nodes. Patients are randomized to radiotherapy or observation following mastectomy and chemotherapy. Radiotherapy will be administered using CT-based therapy. The primary end points of the study are disease-free and overall survival.
Patients will undergo a modified radical mastectomy and level I/II axillary dissection and receive chemotherapy per their institution or on another randomized trial prior to registration for the current study. At time of registration, the patient will be randomized either to observation or local-regional radiotherapy. This protocol is coordinated by the Southwest Oncology Group. The identification number is S9927. Other participating oncology groups are Eastern Cooperative Oncology Group, North Central Cancer Treatment Group, Radiation Therapy Oncology Group, American College of Surgeons, Cancer Leukemia Group B.
For more information, contact Cancer AnswerLine™ 800-865-1125.
A complete database of University of Michigan Cancer Center clinical trials is available online at http://www.cancer.med.umich.edu/learn/trifin.htm.
John Yee, M.D.
Previously served for two years as a thoracic surgery faculty
member at McGill University in Montreal.